---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-025866"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:22:20.183440+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics reports FY2023 net loss $13.3M; cash $8.6M; ReSPECT-LM advances to Cohort 5

## Summary
- Net loss $(13.3)M ($4.24 per share) vs $(20.3)M ($11.58 per share) in 2022; operating loss improved to $13.3M from $19.7M.
- Cash at Dec 31, 2023 was $8.6M, down from $18.1M; runway forecast into 2H 2025.
- Enrolled 5th of 7 dosing cohorts in ReSPECT-LM Phase 1 trial for leptomeningeal metastases; orphan drug designation granted for breast cancer LM.
- Received $3.3M advance from CPRIT grant ($17.6M total); total grant revenue recognized $4.9M in 2023.
- Plans FDA meetings in 2024 to align on pivotal trial design for LM and GBM; registrational trial target 1H 2025.

## SEC filing metadata
- accession: 0000950170-24-025866
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017024025866/0000950170-24-025866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017024025866/pstv-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-025866
- JSON: https://secwatch.observer/filing/0000950170-24-025866.json
- Plain text: https://secwatch.observer/filing/0000950170-24-025866.txt

## Key facts
- Earnings Releases
  PLUS THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2023 results: net income $(13.3) million, or $(4.24) per share, EPS $(4.24) per share.
  - Period: the fourth quarter and year ended December 31, 2023
  - Net income: $(13.3) million, or $(4.24) per share
  - EPS: $(4.24) per share
  - Result: reported results
  source text: Plus Therapeutics, Inc. (the “Company”) reported financial results for the fourth quarter and year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017024025866/0000950170-24-025866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.